Respert: been here since February of 2019 as an in

Quote:

---

Respert: been here since February of 2019 as an investor...over that time it has been clear to me that going at it alone wasn't really the goal

---

I started as an investor about 5-6 months after you, and I can agree, many prior a statements by NP & SK, along with multiple Investors PowerPoints indicated to licensing out every indication. I believe the goal of licensing out our indications has since changed due to our landscape. But to this day, in both our recent NASH PR and today's webcasts, comments were made about aggressively going after partnerships with Big Pharma.

Seems these recurring comments by management is a sign of an impending BP partnership...IMO, regardless of whether a few people want to go solo. I'm for getting Leronlimab out to the masses as fast as possible regardless of path and have no problem sacrificing triple digits for $75/sh (as an example), if that means we can start saving people sooner.